ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 42 of 152 for:    cannabis | Recruiting, Enrolling by invitation Studies

Intracranial Arterial Stenosis and Resin of Cannabis Use

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02246140
Recruitment Status : Recruiting
First Posted : September 22, 2014
Last Update Posted : August 27, 2018
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

Brief Summary:
There is an association between intracranial arterial stenosis and ischemic stroke in young adults. The aim of this study is to evaluate the prevalence of intracranial arterial stenosis in asymptomatic regular resin of cannabis users in comparison with control subjects.

Condition or disease Intervention/treatment Phase
Cannabis Users Other: Cerebral MRI and MRA Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Prevalence of Intracranial Arterial Stenosis in Regular Resin of Cannabis Users Compared to Control Subjects: a Preliminary Study of Feasibility
Study Start Date : July 2014
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana

Arm Intervention/treatment
Experimental: Cannabis users
Cerebral MRI and MRA
Other: Cerebral MRI and MRA
Active Comparator: healthy volunteers
Cerebral MRI and MRA
Other: Cerebral MRI and MRA



Primary Outcome Measures :
  1. Presence of intracranial arterial stenosis on cerebral MRA [ Time Frame: 3 months ]
    Rate on cerebral MRA the presence of cerebral Intracranial Arterial Stenosis segmental narrowing defined by at least two intra-cranial arteries compared with a cohort of non cannabis controls subjects.


Secondary Outcome Measures :
  1. -Silent ischemic stroke on cerebral MRI [ Time Frame: 3 months ]
    Evaluate on cerebral MRI the presence of sequelae of ischemic stroke defined by a parenchymal hyperintensity in a vascular territory defined on a T2 sequence.

  2. -new intracranial arterial stenosis at 3 month follow-up [ Time Frame: 3 months ]
    Evaluate a cerebral MRA at 3 months the presence of new intracranial stenosis among cannabis users, according to the prosecution or stopping use

  3. -Reversibility of intracranial arterial stenosis at 3 month follow-up [ Time Frame: 3 months ]
    Evaluate on cerebral MRA at 3 months reversibility stenosis present at T0 in cannabis users having stopped their consumption



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • regular resin of cannabis users

Exclusion Criteria:

  • taking vasoactive medications
  • taking other illicit drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02246140


Contacts
Contact: Valerie Wolff, MD 03 88 12 86 06 ext 0033 valerie.wolff@chru-strasbourg.fr

Locations
France
Hôpitaux Universitaires de Strasbourg Recruiting
Strasbourg,, France, 67091
Contact: Valerie Wolff, MD    03 88 12 86 06 ext 0033    valerie.wolff@chru-strasbourg.fr   
Principal Investigator: Valerie Wolff, MD         
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Principal Investigator: Valerie Wolff, MD University Hospital, Strasbourg, France

Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT02246140     History of Changes
Other Study ID Numbers: 5715
First Posted: September 22, 2014    Key Record Dates
Last Update Posted: August 27, 2018
Last Verified: August 2018

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders